4.757
an Open Access Journal by MDPI

Therapeutic Potential of Molecular Hydrogen in Human Diseases
Guest Editors:

Message from the Guest Editors

Dr. Shin-Ichi Hirano
Department of Research andDevelopment, MiZ Company
Limited, Kanagawa, Japan

Molecular hydrogen (H2) was identified as an antioxidantthat directly reduces hydroxyl radicals (·OH) andperoxynitrite. H2 also exerts indirect antioxidant, antiinflammatory, and antiapoptotic eﬀects via the regulationof gene expression. Other indirect mechanisms throughwhich H2 exerts its eﬀects have been reported, such asnuclear factor erythroid-related factor 2 and various
signaling pathways in cells. A target molecule of H2 wasrecently identified that indicates that an oxidized form ofporphyrin catalyzes the reaction of H2 with ∙OH to reduce
oxidative stress; however, the details of the mechanistic
actions of H2, including its target molecules, true clinicalviability, and the appropriate doses as well as dosages forindividual human diseases, are still in the initial stages.

s_hirano@e-miz.co.jp
Prof. Dr. Yoshiyasu Takefuji
1. Faculty of Data Science,Musashino University, Tokyo,Japan
2. Professor Emeritus, Faculty ofEnvironmental Information, Keio
University, Tokyo, Japan
takefuji@keio.jp

Deadline for manuscript
submissions:
31 October 2023

mdpi.com/si/174952

This Special Issue is seeking contributions that will further
elucidate the potential therapeutic use of H2 in humandiseases. Both in vitro cellular and in vivo animal studies
are of interest. Authors are invited to submit original
research articles and reviews that advance ourunderstanding of the therapeutic potential of H2 in thetreatment of various human diseases.

SpecialIssue

4.757
an Open Access Journal by MDPI
Editor-in-Chief

Message from the Editor-in-ChiefProf. Dr. Shaker A. Mousa
The Pharmaceutical ResearchInstitute, Albany College of
Pharmacy and Health Sciences, 1
Discovery Drive (Room 238),
Rensselaer, NY 12144, USA

Biomedicines (ISSN 2227-9059) is an open access journal
devoted to all aspects of research on human health anddisease, the discovery and characterization of new
therapeutic targets, therapeutic strategies, and research ofnaturally driven biomedicines, pharmaceuticals, andbiopharmaceutical products. Topics include pathogenesis
mechanisms of diseases, translational medical research,biomaterial in biomedical research, natural bioactive
molecules, biologics, vaccines, gene therapies, cell-basedtherapies, targeted specific antibodies, recombinant
therapeutic proteins, nanobiotechnology driven products,
targeted therapy, bioimaging, biosensors, biomarkers, andbiosimilars. The journal is open for publication of studies
conducted at the basic science and preclinical researchlevels. We invite you to consider submitting your work toBiomedicines, be it original research, review articles, ordeveloping Special Issues of current key topics.

Author Benefits
Open Access:— free for readers,with article processing charges (APC) paid by authors or
their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC,CAPlus / SciFinder, and other databases.
Journal Rank: JCR - Q2 (Biochemistry & Molecular Biology) / CiteScore - Q2 (Medicine(miscellaneous))

Contact Us
Biomedicines
MDPI, St. Alban-Anlage 664052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicinesbiomedicines@mdpi.com@Biomed_MDPI